Leukocytoclastic vasculitis due to etanercept.

  • 1 August 2000
    • journal article
    • case report
    • Vol. 27  (8) , 2041-4
Abstract
Recently etanercept, a soluble recombinant tumor necrosis factor receptor:Fc fusion protein, became available to treat patients with rheumatoid arthritis (RA). Among adverse reactions are cutaneous side effects, which occur in about 5% of patients. These have included mostly injection site reactions as well as urticarial reactions. We describe the first case of leukocytoclastic vasculitis associated with the use of etanercept in a patient with severe, deforming RA previously unresponsive to multiple therapies. Discontinuation of the drug led to complete resolution of the vasculitis.

This publication has 0 references indexed in Scilit: